If you have frequent headaches, pay attention to this study!
-Click onThe blue word ↑ [Enshi Release]ToFollow me-
In January this year, Enshi Central Hospital launched a randomized, double-blind, comfort-controlled clinical trial study to evaluate the efficacy and safety of Headache Ning Capsules in the treatment of migraine (stasis-blocking evidence) attacks, which was openly recruited for the community and received wide attention from the society.
The clinical study is still ongoing, and the team has received many inquiries from patients through various channels such as the Internet and telephone. In order to let more patients understand and benefit from the study, the research team of the project at the State Central Hospital is now answering the following information related to patients' concerns.
Q
What kind of headache needs to be concerned and receive standardized treatment?
Expert answer:Headache is one of the common clinical symptoms and almost everyone experiences headache, which is divided into secondary and primary headache. Migraine is the most common type of primary headache in clinical practice and is mainly characterized by episodes of moderately severe, throbbing headache lasting 4-72 hours, which can be aggravated by light or sound stimulation or daily activities, accompanied by nausea or vomiting, photophobia or phonophobia. The latest Global Burden of Disease Study shows that 1.25 billion people worldwide suffered from migraine in 2017, making it the sixth most common disease in the world. The disease has a high incidence and recurrence rate in the population, and can last for years to decades, making it difficult to recover and seriously affecting one's life and work.
Q
Why did the state central hospital start this study and what is the basis of this study?
Answer:The "Randomized, double-blind, comfort-controlled clinical trial study to evaluate the effectiveness and safety of Headache Ning Capsules in the treatment of migraine attacks (blood stasis blockage)" was initiated by our hospital based on the fact that Headache Ning Capsules is our "star homemade medicine". The drug is a Chinese medicine preparation approved by the Provincial Drug Administration and developed by our hospital, which has been used in hospitals for more than 20 years and has been well received by patients. Ltd. And Yuanda Pharmaceutical (China) Co., Ltd. Will fully utilize the professional advantages and resources of both hospitals and enterprises to carry out all-round cooperation in the field of drug research and development, and promote drug preparation and frontier innovation research, transformation of results and development and marketing. As a "star homemade medicine", the headache capsule will be developed and marketed first. In order to understand more objectively the efficacy of headache capsules in the treatment of migraine and to give more migraine patients a chance to control and improve their condition, the headache specialist team of the Department of Brain Diseases of our hospital has initiated this research project.
Q
What is the pharmacology of Headache Nimble Capsules in treating headache? How effective is it?
Answer:Headache Ning Capsule is an experienced formula based on folk prescriptions, which consists of 11 herbs, such as Radix et Rhizoma Ginseng, Rhizoma Tenuifolia and Radix Salviae Miltiorrhizae. Its function is to invigorate blood circulation and eliminate blood stasis, regulate qi, tonify deficiency, dispel wind and open collaterals, and is used for headache caused by qi deficiency and blood stasis. For primary headache, especially migraine, you can choose Headache Ning Capsules. 20 years of practice has proved that Headache Ning Capsules can not only reduce the symptoms of headache, but more importantly, reduce the number of attacks and prevent recurrence, which can help to solve the root of headache annoyance.
Q
Who are the patients suitable to participate in this study?
Answer:The following groups of patients are suitable for participation: aged between 18 and 60, with the first migraine attack at age ≤ 50; diagnosed with headache disease in Chinese medicine, with evidence of blood stasis and obstruction; migraine disease duration ≥ 1 year, with ≥ 2 attacks per month in the last 3 months, and the number of headache days is less than 15 days per month; patients voluntarily sign the informed consent form. The full version of the inclusion criteria is detailed in the study protocol.
Q
What are the possible benefits for patients who participate in this study?
Expert Answer:The potential benefits to patients and society from this study include the potential for improvement in headache symptoms and the potential for this study to support the marketing of a new herbal medicine for migraine for use in other patients with similar conditions; patients will receive good medical care during the study period.
Q
What services and benefits are available to patients participating in this study?
Answer:Patients will be provided with tests and treatment medications related to this clinical trial free of charge; patients will receive a travel subsidy for participating in this study.
Q
How can I enroll in the study?
Answer:You can call the research team of the project (Huang Nianping 13872720234, Huang Xinquan 13971895543, Li Xuejie 13872735758) to sign up. You can also inquire about the matter at the outpatient clinic of the Department of Brain Diseases on the second floor of the General Building of the Department of Traditional Chinese Medicine of the State Central Hospital (Enshi Prefecture Ethnic Hospital). All patients who meet the requirements by pre-enrollment screening will have the opportunity to participate in the clinical study.
Source: Enshi Prefecture Central Hospital
Editor: Tan Qionghui
Review | Zhang Xiaoling
Issued by Liu Shenhong